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the use of other antibiotics. We conducted a subsequent
study to determine the impact of the policy on resistance
rates.
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OBJECTIVE: It has been asserted that “decisions regard-
ing the allocation of public HIV prevention funds repre-
sent the single most important set of HIV prevention
decisions made,” (Ruiz et al., 2000; p.19). As a result,
several approaches to allocating these funds have been
proposed. However, the application of these models is
limited because the measurements of performance are
usually not quantiﬁable in real practice. This research
outlines a resource allocation model that can be used 
to assist decision-makers in allocating HIV prevention
funds. METHODS: The current process of allocating
HIV prevention funds within various states was reviewed
in detail. Speciﬁcally, population subgroup, intervention,
and geographical issues were considered. In addition,
measures of successful intervention implementation were
identiﬁed. After this thorough review, parameters (i.e.,
prevalence, infectivity, input from local planning groups)
deemed to be important in determining the proper allo-
cation of funds were identiﬁed. These parameter choices
were guided by the need to be able to estimate parame-
ter values from available data systems. Using linear pro-
gramming techniques, a model based on our parameter
choices was developed for used by decision-makers that
incorporates a quantiﬁable measure of success. This
model also includes funding and equity constraints.
RESULTS: An allocation of funds can be made such that
several system constraints can be considered and the
model can be validated through prospective data collec-
tion. The model was programmed in Microsoft Excel®
with a user-friendly interface and was prototyped within
a state health department’s allocation system.
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OBJECTIVES: Current guidelines recommend pravas-
tatin or atorvastatin, and not lovastatin or simvastatin,
to avoid drug interactions in PI-treated HIV+ patients
requiring dyslipidemia treatment. Because limited data
are currently available on the historical management 
of dyslipidemia within the PI-treated HIV+ population,
we examined the annual utilization trend of non-
recommended HMG-CoA reductase inhibitors (statins)
within this population. METHODS: This was a retro-
spective, cross-sectional analysis using pharmacy claims
from 1998–2001 from a managed care organization
(MCO) of about 3.5 million lives. Patients with at least
2 claims for antiretroviral therapy with a cumulative
days’ supply >30 and concurrent statin-PI utilization
during the same calendar year were included. Logistic
regression was used to evaluate whether age, gender, 
or physician specialty were associated with non-
recommended statin use. RESULTS: There were 4 non-
mutually exclusive yearly cohorts with 492 unique HIV+
patients with concurrent statin-PI therapy (1998 :n = 141;
1999 :n = 224; 2000 :n = 231; 2001 :n = 250). Mean ages
ranged from 45.7–47.3 years and >95% were male. There
were 58 occurrences (6.9%) of concurrent simvastatin-PI
utilization between 1998–2001. No concurrent lovas-
tatin-PI was identiﬁed. Most patients (72.5%) received
their statins and PI from the same physician. Patients
receiving these medications from different physicians
were signiﬁcantly more likely to have concurrent simvas-
tatin-PI utilization (OR: 2.01, 95% CI: 1.13–3.58).
Although no overall trend in simvastatin-PI utilization
was observed, a signiﬁcant decreasing trend was seen
among infectious disease (ID) physicians (p = 0.04).
CONCLUSIONS: As this patient population and its
longevity grow, the quality of their management becomes
increasingly important. Since simvastatin and lovastatin
were not on this MCO’s formulary, the prevalence of non-
recommended statin use was low. Nevertheless, we found
a proportion of patients who received concurrent sim-
vastatin-PI and a decreasing utilization trend among ID
physicians as guidelines became better established.
Awareness, however, among non-ID physicians may still
need to be improved and greater coordination established
between different physician prescribers of statin and PI
therapy.
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OBJECTIVES: To assess potential implications of 
applying four competing national guidelines addressing
antibiotic prophylaxis of Total Hip Replacement (THR)
surgery. METHODS: Four guidelines were applied to a
random sample of 386 medical records of patients who
underwent THR surgery from January 1999 to Decem-
ber 2000. Setting: Orthopaedic surgery wards in a 2200-
bed French teaching hospital. Main outcome measure:
Compliance of physician practice with the French guide-
line (French National Agency of Accreditation and Health
